PRC2-dependent repression of antigen processing pathways has previously been identified as a conserved mechanism for immune evasion by tumor cells that can potentially be counteracted by PRC2 inhibition, including in lymphoma cells carrying EZH2 gain-of-function mutations51–53. The gene discussed is EZH2; the disease is neoplasm.